The UK's Competition and Markets Authority (CMA) is once again cracking down on Actavis UK, this time alleging that the company signed illegal agreements with Concordia International Corp. that enabled Actavis's price hikes for generic hydrocortisone tablets to be prolonged in the UK. Over the last year, the CMA has fined Actavis once for its part in an anti-competitive deal with GlaxoSmithKline PLC and launched two investigations into its conduct in the UK.
In a March 3 statement, the CMA says a pay-for-delay agreement between Actavis and Concordia, which has spanned...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?